Balaglitazone is a second generation peroxisome proliferator-activated receptor (PPAR) gamma agonist with only partial agonistic properties. It passed phase III clinical trial for the treatment of type 2 diabetes. However, Dr. Reddy's Laboratories decided to terminate further clinical development of balaglitazone.

Doconazole is the antifungal agent. It is the first of the dioxolane series, which was later to produce ketoconazole, to appear as a potential drug. Antifungal activity of doconazole was compared with miconazole and amphotericin B activity against a number of pathogenic filamentous fungi. Doconazole was found to be more active than miconazole only against Coccidioides immitis and less active against A.fumigatus, B. dermatitidis, H.capsulatum and S.schenckii. Doconazole has been described as the drug of choice for oral treatment of murine coccidioidomycosis but was dropped because it produced glaucoma in dogs. Doconazole is used for the treatment of infections of the skin and mucous membranes caused by the Herpes simplex type 1 virus, including herpes of lips. Docosanol affects the fusion of the virus with the plasma membrane, which inhibits the penetration of the virus into the cell and its subsequent replication. Side effects are: dry skin, pruritus, rash, short-term redness, soreness, peeling, burning or tingling.

Oxfenicine is a CPT-1b-specific inhibitor. It must be transaminated to its active form, 4-hydroxyphenyl-glyoxylate, which is competitive with carnitine, preventing the formation of acylcarnitine. Because CPT-1b shows the highest sensitivity to 4-hydroxyphenyl-glyoxylate, inhibition of fatty acid oxidation by oxfenicine takes place selectively in those tissues that express this CPT isoform. It may be effective for treating noninsulin-dependent diabetes mellitus which is characterized by elevated fatty acid levels and obesity. In 1980 it was also tested in preclinical models of angina pectoris and ischemia.

Isamoltan (CGP 361A) is a β-adrenoceptor and serotonin 1B receptor antagonist. Isamoltane has reported activity as an anxiolytic in man. Isamoltan had been in phase III clinical trials for the treatment of anxiety. However, this research has been discontinued.

Tecarfarin (also known as ATI-5923), an anticoagulant, is a vitamin K reductase antagonist. Tecarfarin is participating in phase III clinical trials for the treatment of thromboembolism and thrombosis. On March 11, 2019, Espero BioPharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for tecarfarin for the prevention of systemic thromboembolism of cardiac origin. Tecarfarin is metabolized by esterases, escaping metabolism by the cytochrome P450 system and thereby avoiding cytochrome P450-mediated drug-drug or drug-food interactions as well as genetic variations found in the cytochrome P450 system.

Tecastemizole (aka Norastemizole) is an H1 receptor antagonist that showed great promise as potential next-generation antihistamine allergy medication. Sepracor developed Norastemizole through phase III clinical trials; however, the FDA rejected the application for approval on the grounds of an unacceptable profile of adverse side-effects including phospholipidosis and cardiomyopathies in animals exposed to the drug.

Meciadanol (O-methyl-3(+)catechin or Zy 15029), a synthetic flavonoid, is an inhibitor of histamine-forming enzyme histidine decarboxylase. It prevents stimulus-dependent gastric acid secretion. Meciadanol was shown to have a marked protective action against experimental peptic ulceration.

Colforsin (NKH477) is a water-soluble forskolin derivative. NKH477, like forskolin, showed adenylate cyclase stimulant activity in guinea pig ventricular membrane but did not inhibit Na+, K(+)-ATPase or phosphodiesterase (PDE) activity. The compound was developed by a Japanese company Nippon Kayaku. Colforsin daropate, a prodrug of colforsin, is marketed in Japan for the treatment of acute heart failure under tradename Adehl.

Uldazepam is a tranquilizer belonging to the 1.4‐benzodiazepine group.